Connecticut Capital Management Group LLC Takes Position in Johnson & Johnson $JNJ

Connecticut Capital Management Group LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,222 shares of the company’s stock, valued at approximately $667,000.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. AustralianSuper Pty Ltd increased its stake in Johnson & Johnson by 632.0% in the third quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after purchasing an additional 77,000 shares during the last quarter. J.W. Cole Advisors Inc. grew its position in Johnson & Johnson by 2.2% during the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after acquiring an additional 2,769 shares during the period. Guinness Asset Management LTD grew its position in Johnson & Johnson by 0.4% during the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after acquiring an additional 5,994 shares during the period. Greenberg Financial Group purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $954,000. Finally, National Pension Service grew its position in Johnson & Johnson by 3.2% during the third quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after acquiring an additional 151,707 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced it will hold its second-quarter earnings conference call on July 15, reinforcing near-term focus on results, guidance, and management commentary. Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
• Positive Sentiment: DePuy Synthes, J&J’s orthopedic business, struck an exclusive distribution deal for the NOVOSIS bone graft product, adding another growth-oriented medtech move. DePuy Synthes secures exclusive NOVOSIS bone graft distribution partnership
• Positive Sentiment: Market commentary highlighted J&J as one of several large-cap pharma stocks worth holding as the industry recovery accelerates, supporting sentiment toward the stock. 4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
• Positive Sentiment: J&J was reported to have an average brokerage recommendation of “Moderate Buy,” suggesting analysts remain constructive on the shares. Johnson & Johnson Receives Average Recommendation of Moderate Buy from Brokerages
• Neutral Sentiment: J&J also presented at Bernstein’s Strategic Decisions Conference, but the transcript does not point to a fresh, stock-moving surprise by itself. Johnson & Johnson Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
• Negative Sentiment: Talc litigation remains an overhang, with new verdict headlines reinforcing legal risk that could pressure valuation multiples. Assessing Johnson & Johnson Valuation After Guidance Raise Growth Initiatives And Talc Litigation Update
• Negative Sentiment: Broader healthcare weakness also weighed on sentiment, with pharma and healthcare stocks described as a drag on the market in recent trading. Dow Gives Back Early Gains. Healthcare Stocks Are a Drag.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Johnson Rice raised Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Citigroup upped their target price on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Daiwa Securities Group upped their target price on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research report on Thursday, April 16th. Finally, Stifel Nicolaus upped their target price on Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Trading Up 0.5%

NYSE:JNJ opened at $231.38 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71. The business’s 50-day simple moving average is $233.41 and its 200 day simple moving average is $224.50. The stock has a market cap of $556.97 billion, a price-to-earnings ratio of 26.75, a price-to-earnings-growth ratio of 2.25 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. During the same quarter in the previous year, the firm posted $2.77 earnings per share. The company’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s payout ratio is presently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.